Immutrin is developing a novel antibody intended to selectively bind amyloid fibrils and trigger immune-mediated depletion of established amyloid deposits. Its lead program is focused on ATTR cardiomyopathy, with the company positioning the asset as potentially best-in-class for amyloid removal and noting possible applicability to other amyloidosis types. The company was co-founded by Cambridge Innovation Capital and academics Professor Sir Mark Pepys, Sir Gregory Winter and Professor Daniel Christ and is headquartered in Cambridge, UK. Immutrin recently raised £65 million ($87 million) in a Series A to fund its lead asset through clinical proof of concept. Management includes CEO Mihriban Tuna and new CFO/COO Tolga Hassan, and the board will include representatives from Frazier, F-Prime, Qiming and Cambridge Innovation Capital. The company emphasizes its scientific foundation based on decades of work on amyloid biology and antibody engineering.

Total raised

$87M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2026